Relapsing-remitting Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Relapsing-remitting Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: A Study to Evaluate Pharmacokinetics, Safety, Tolerability, Immunogenicity and Pharmacodynamic Effects of Subcutaneous Ocrelizumab Administration in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS) [Phase 2]
A Phase 2 study to evaluate pharmacokinetics, safety, tolerability, immunogenicity and pharmacodynamic effects of subcutaneous ocrelizumab i…
-
CLINICAL_TRIALS research · 2026-04-20Clinical Trial Update: The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study [NA]
A pilot clinical trial evaluating the SetPoint System as a pro-remyelination therapy for relapsing-remitting multiple sclerosis is currently…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS Patients
This is an Italian multicenter, prospective observational study evaluating Ofatumumab in Relapsing-Remitting multiple sclerosis, sponsored b…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Safety and Efficacy of Extracorporeal Photopheresis (ECP) in the Treatment of Multiple Sclerosis [Phase 1, Phase 2]
A Phase 1/2 clinical trial is assessing the safety and efficacy of Extracorporeal Photopheresis for Multiple Sclerosis, including Relapsing-…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: The HIt HArd and hiT Early in Multiple Sclerosis Trial [Phase 2]
A Phase 2 clinical trial update for Relapsing-remitting multiple sclerosis led by Uppsala University, currently not yet recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Study Utilising Data From European Union (EU) National Multiple Sclerosis (MS) Registries to Assess the Incidence of Anti-Natalizumab Antibody Among Participants Who Receive Subcutaneous Administration of Natalizumab for Treatment of Relapsing-remitting Multiple Sclerosis (RRMS)
Biogen-sponsored study leveraging EU MS registry data to assess the incidence of anti-natalizumab antibodies in relapsing-remitting multiple…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple Sclerosis [Phase 4]
A Phase 4 clinical trial to evaluate the safety and efficacy of fingolimod in Taiwanese adults with relapsing-remitting multiple sclerosis i…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Functional Outcomes From Diets in Multiple Sclerosis [NA]
This clinical trial update reports on functional outcomes from dietary interventions in people with relapsing-remitting multiple sclerosis a…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Hyperpolarized Carbon Metabolic Imaging in Multiple Sclerosis [Phase 2]
Phase 2 clinical trial update investigating hyperpolarized carbon metabolic imaging as a biomarker in multiple sclerosis, currently not yet …
-
CLINICAL_TRIALS research · 2026-03-30Clinical Trial Update: A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) Elevation [Phase 4]
A Phase 4 multicenter study compares continuing current multiple sclerosis therapy versus transitioning to ofatumumab after elevated neurofi…
-
CLINICAL_TRIALS research · 2026-03-27Clinical Trial Update: The Prevalance of Malnutrition and Its Association With Disability in Patients With Relapsing-Remitting Multiple Sclerosis
This ClinicalTrials.gov update outlines a study assessing the prevalence of malnutrition in patients with relapsing-remitting multiple scler…
-
CLINICAL_TRIALS research · 2026-03-24Clinical Trial Update: Exploration of Novel Imaging Biomarkers on OCT for Ublituximab Treatment Response in Multiple Sclerosis [NA]
A clinical trial update notes a study exploring OCT imaging biomarkers to evaluate Ublituximab treatment response in relapsing-remitting mul…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: ELIOS - Investigational Biomarkers to Track Disease Modification in Active RRMS [Phase 4]
Phase 4 clinical trial update for ELIOS investigating investigational biomarkers to track disease modification in active Relapsing Remitting…
-
CLINICAL_TRIALS research · 2026-03-20Clinical Trial Update: Intermittent Hypoxia in Persons With Multiple Sclerosis [NA]
A clinical trial update indicates a study evaluating intermittent hypoxia in people with Multiple Sclerosis is currently recruiting.
-
CLINICAL_TRIALS research · 2026-03-17Clinical Trial Update: Ublituximab (Briumvi) for Early Forms of Relapsing Multiple Sclerosis [Phase 4]
A Phase 4 clinical trial evaluating Ublituximab (Briumvi) for early forms of relapsing multiple sclerosis is currently recruiting. Sponsored…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis [Phase 3]
Phase 3 clinical trial update evaluating IMU-838 (vidofludimus) for relapsing-remitting multiple sclerosis; currently active but not recruit…
-
CLINICAL_TRIALS research · 2026-02-23Clinical Trial Update: The Synergistic Effects of AIH and FES in Persons With MS [NA]
This clinical trial update covers a study evaluating the synergistic effects of AIH and Functional Electrical Stimulation (FES) in people wi…
-
CLINICAL_TRIALS research · 2026-02-19Clinical Trial Update: Dendritic Cells Therapy Combined With Immunomodulatory Treatment in Multiple Sclerosis [Phase 2]
A Phase 2 clinical trial evaluating dendritic cell therapy combined with immunomodulatory treatment for Relapsing-Remitting Multiple Scleros…
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Effects of Ublituximab on Motor Functions in Multiple Sclerosis [EARLY_Phase 1]
An early-phase 1 trial is evaluating the effects of ublituximab on motor function in relapsing-remitting multiple sclerosis and is currently…
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis [Phase 3]
This document describes a Phase 3 pediatric trial comparing ozanimod to fingolimod in children and adolescents with relapsing-remitting mult…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: RItuximab Versus Ocrelizumab in Relapsing-remitting Multiple Sclerosis. [Phase 3]
Phase 3 clinical trial comparing Rituximab versus Ocrelizumab for relapsing-remitting multiple sclerosis is currently recruiting.
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-Remitting Multiple Sclerosis (RRMS) [Phase 3]
Clinical trial update describing a Phase 3 study comparing ocrelizumab with fingolimod for safety and efficacy in children and adolescents w…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis [NA]
A clinical trial investigating indole-3-propionic acid for relapsing-remitting multiple sclerosis is currently recruiting in Copenhagen. Spo…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Home Based Functional Balance Intervention for Multiple Sclerosis [NA]
A clinical trial is recruiting to evaluate a home-based functional balance intervention for people with multiple sclerosis. The study appear…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
A clinical trial update for a study evaluating the usability and value of integrated digital solutions in the care of participants with Rela…